MediMabBio, a biopharmaceutical company developing next-generation fusion antibody therapeutics, has been selected to join the “Bio Materials, Parts, and Equipment (Bio-MPE) Alliance Council” by the Korea Biotechnology Industry Organization. This selection highlights the company’s differentiated technology and strong potential for global innovation.
The council was established to support over 90 domestic biotech companies by facilitating joint R&D and strengthening supply chain resilience through the localization of critical raw materials. As a member, MediMabBio will receive support to reduce reliance on external suppliers and enhance its research infrastructure.
Through active collaboration within the council, MediMabBio plans to initiate joint projects, exchange cutting-edge technologies, and accelerate the commercialization of its antibody pipeline. The company also aims to expand global partnerships as part of its mid- to long-term growth strategy.